Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review
Cancers · 26.11.2025 · 17 (23) · 3786
DOI: 10.3390/cancers17233786 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.11.2025. Verfasst von Alexandra-Simona Zamfir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences III, Pulmonology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rituximab, a monoclonal antibody targeting CD20, has revolutionized the management of B-cell lymphoproliferative disorders and some immune conditions, significantly improving disease control and patient survival. Beyond its indisputable therapeutic benefits, rituximab can cause serious pulmonary adverse events, particularly interstitial lung disease (R-ILD). Diagnosing R-ILD is challenging due to nonspecific clinical and imagistic features, and its true incidence is possibly underestimated.
Methods
We conducted a systematic review to synthesize current evidence on R-ILD, focusing on its incidence, diagnostic approaches, management strategies and clinical outcomes. A comprehensive search of PubMed/MEDLINE was performed using the term “rituximab induced interstitial lung disease” through August 2025. Relevant abstracts were screened, and full-text articles meeting the inclusion criteria were analyzed.
Results
A total of 40 studies were retained after the search and screening, including case reports, case series and cohort studies of R-ILD. This condition was identified in both malignant and autoimmune disorders receiving rituximab, more frequently for combination regimens. Radiological manifestations were heterogeneous, and ground-glass opacities were the dominant pattern. Most R-ILD cases were reversible, but progression to chronic interstitial disease and fatal outcomes are possible. Cohort studies demonstrated variability in incidence, reported instances of successful rituximab reintroduction and suggested a protective effect of prophylactic trimethoprim-sulfamethoxazole against opportunistic pneumonitis.
Conclusions
Although rare, R-ILD is a clinically significant complication of rituximab therapy. Early recognition and multidisciplinary management are essential, as most patients respond to corticosteroids, while severe cases may progress to respiratory failure or fatal outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Sciences III, Pulmonology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Oncology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Medical Oncology, Regional Institute of Oncology, 700483 Iasi, Romania.
- Department of Morpho-Functional Sciences I, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Morpho-Functional Sciences II, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Oncology, Emergency County Hospital, 400006 Cluj-Napoca, Romania.
ORCID-Profile: Mihai-Vasile Marinca, Carmen Lăcrămioara Zamfir, Gabriela Bordeianu, Andrada-Larisa Deac, Bogdan-Mihnea Ciuntu, Tudor Andrei Cernomaz
Zitieren
APA
Zamfir, A. S., Marinca, M. V., Zamfir, C. L., Bordeianu, G., Deac, A. L., Ciuntu, B. M., Pintilie, C. T., Ojog, D., Brînză, M., & Cernomaz, T. A. (2025). Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review. Cancers, 17(23), 3786. https://doi.org/10.3390/cancers17233786
Vancouver
Zamfir AS, Marinca MV, Zamfir CL, Bordeianu G, Deac AL, Ciuntu BM, et al. Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review. Cancers. 2025;17(23):3786. doi:10.3390/cancers17233786
BibTeX
@article{Zamfir2025,
author = {Zamfir, Alexandra-Simona and Marinca, Mihai-Vasile and Zamfir, Carmen Lăcrămioara and Bordeianu, Gabriela and Deac, Andrada-Larisa and Ciuntu, Bogdan-Mihnea and Pintilie, Cătălina Teodora and Ojog, Doina and Brînză, Marcela and Cernomaz, Tudor Andrei},
title = {Rituximab-Induced Interstitial Lung Disease: A Possible Underestimated Complication—A Systematic Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {23},
pages = {3786},
doi = {10.3390/cancers17233786}
}
EUVIMED